CAR-T细胞疗法市场按适应症、细胞来源、代数、治疗线、标靶抗原和最终用户划分－2025-2032年全球预测

预计到 2032 年，CAR T 细胞疗法市场将成长至 138.7 亿美元，复合年增长率为 15.06%。

关键市场统计数据
基准年 2024	45.1亿美元
预计年份：2025年	51.9亿美元
预测年份 2032	138.7亿美元
复合年增长率 (%)	15.06%

一份简明扼要的CAR T细胞疗法策略指南，整合了科学进展、生产实际情况、监管动态和商业性准入的考量。

CAR-T细胞疗法领域正处于前沿免疫肿瘤学和复杂商业性运作的交汇点。本执行摘要整合了临床进展、转化创新、监管动态、日趋成熟的生产技术以及不断变化的医疗服务模式，共同描绘了CAR-T领域的现状。本摘要旨在指南企业主管、临床负责人、投资者和政策制定者了解影响研发重点和营运决策的各项因素。

在简要概述了治疗机制和按适应症分類的临床表现后，摘要转向实际考量，例如生产能力、供应链韧性以及不断发展的即时诊疗模式。文章始终强调将科学进步与商业性可行性联繫起来的实用见解。文章揭示了模组化生产平台、抗原选择策略和新一代构建体如何转化为差异化的临床特征和新的应用模式。同时，支付方合作和真实世界证据的产生正成为影响药物可近性和应用率的关键因素。

总的来说，本引言透过阐述技术、监管和经济发展如何重塑相关人员的CAR-T 策略的整合过程，为后续章节提供了一个框架，从而支持有关投资、伙伴关係和营运设计的知情决策。

技术、监管、製造和商业性变革将共同重塑 CAR-T 疗法的研发和病患获取途径。

CAR-T细胞疗法正经历一系列变革，这些变革超越了简单的产品改进，从根本上改变了其研发和给药的结构。载体工程、共刺激结构域选择和抗原标靶化的进步，不仅拓展了治疗范围，也提升了安全性和持久性。这些技术进步与製造创新相辅相成，例如分散式和自动化平台，从而缩短了生产时间，并降低了每剂药物的操作复杂性。随着这些技术变革的推进，将集中式专业知识与即时治疗相结合的新型商业模式正在涌现。

监管路径也在同步调整，监管机构越来越愿意考虑真实世界数据和适应性开发策略，以平衡快速应用和长期安全监测。同时，医疗系统正在重建基础设施，以支持在传统住院医疗机构之外开展CAR-T疗法，而支付方也开始试验按绩效付费的合约模式，以使成本与临床获益相匹配。这些变化共同推动着治疗模式从单一产品、高成本的干预措施转向更具扩充性、以循证医学为导向的项目，这些项目优先考虑可持续的疗效和广泛的患者覆盖。能够预见并应对这些转变的相关人员将更有能力将科学领先优势转化为持续的临床和商业性影响。

因应2025年关税变化对供应链韧性、製造地选择和临床试验物流的影响的营运和策略措施

美国将在2025年实施的新关税为先进细胞疗法的经济和物流带来了新的变数。对进口原料、一次性组件和某些生物加工设备征收关税，增加了上游成本，并导致供应商选择的不确定性。这种情况促使製造商和临床中心重新评估其筹资策略，寻找替代供应商，并考虑加强关键供应链的垂直整合。短期内，由于采购团队需要评估关税的影响并协商修改后的条款，因此采购週期预计将会延长。

除了采购之外，关税带来的成本压力也会影响製造地决策。企业可能会加快对国内生产能力的投资，以降低跨境关税风险。或者，他们可能会寻求区域合作，以实现关键流程的本地化，例如载体生产和填充表面处理工程。临床试验申办方需要重新评估其预算假设，并可能优先考虑拥有附近製造地或冗余供应设施的机构，以降低物流风险。同时，提供输液服务的医院和门诊中心也需要调整其耗材库存和资本设备采购计画。

整体而言，2025年的关税不会改变CAR-T疗法的科学潜力，但会影响其商业营运决策。积极采取供应链多元化、在可行的情况下进行策略性本土化生产以及与供应商达成合作协议的相关人员，将能够减轻中断影响，确保患者治疗的连续性，并保持研发和商业化的势头。

基于细分市场的洞察揭示了适应症、细胞来源、世代、治疗线、抗原标靶和治疗环境如何决定研发和商业化路径

详细的市场细分揭示了治疗和给药领域中细微的驱动因素和清晰的机会点。依适应症划分，市场涵盖白血病（细分为急性淋巴性白血病和急性骨髓性白血病）、多发性骨髓瘤和非何杰金氏淋巴瘤（瀰漫性大B细胞淋巴瘤、滤泡性淋巴瘤和套细胞淋巴瘤构成具体的临床亚型）。每种适应症都有其独特的疗效预期、安全性考量和证据要件，这些都会影响临床实验设计和商业化策略。就细胞来源而言，异体疗法能够实现即时给药并加快治疗启动速度，而自体疗法在个人化生产与已确立的安全性和有效性记录相符的领域仍然具有重要意义。

代间差异也影响临床和营运模式。第一代产品旨在概念验证；第二代产品整合了优化的共刺激结构域；第三代方法结合了多种信号通路元件以提高持久性；第四代设计则整合了细胞激素表达和安全开关等功能，以拓展治疗潜力。治疗方案（第一线治疗与復发/难治性治疗）会影响临床试验终点和医保支付方的讨论，因为早期治疗优先考虑安全性和长期疗效，而復发/难治性治疗则强调快速反应。标靶抗原的选择（尤其是BCMA和CD19）持续推动着针对特异性适应症的治疗策略和伴随诊断的开发。最后，终端使用者群体——学术机构、医院、门诊肿瘤中心和专科诊所——决定了培训、基础设施和诊疗路径投资的有效性，从而影响部署顺序和医护人员之间的合作。

区域法规环境、生产策略和交付能力如何导致全球市场获得 CAR-T 疗法的机会差异

区域趋势对监管预期、生产策略和医疗服务模式有着深远的影响。在美洲，密集的专科医疗网络、历来充满活力的创投生态系统以及灵活的监管路径，促进了早期临床应用和商业化策略的实施，这些策略强调本土生产和真实世界证据的生成。同时，在欧洲、中东和非洲地区，管理体制的多样性和报销制度的不均衡，要求制定个性化的卫生经济学论证和以社区为基础的参与计划，同时也为构建能够服务于多个市场的区域性製造地提供了机会。

亚太地区正经历快速的产能建设，国内对细胞治疗平台的投资不断增加，临床试验规模也在扩大，加速了病患招募和疗效比较研究。各地区在基础建设、劳动力发展和医保报销政策上的差异，影响药物普及的速度和规模。因此，製造商正在根据区域特性建立製造地、监管策略和商业性伙伴关係，以优化产品上市顺序和定价模式。包括许可、联合开发和战略生产联盟在内的跨区域合作，正逐渐成为兼顾全球目标与本地实际情况和监管差异的切实可行的途径。

透过製造规模、创新和一体化商业性支援来驱动竞争优势的企业策略和合作模式

CAR-T疗法生态系统中的领先机构正在寻求策略合作伙伴关係，以确保供应链安全并扩大临床应用范围，同时推动多样化的架构设计、抗原标标靶化和生产方法。产业相关人员正在投资模组化、自动化生产平台，以缩短週期时间并提高可重复性，并加强与学术机构和契约製造的合作，以扩大产能。一些公司正透过专注于多抗原标靶化的下一代工程方法来实现差异化，以提高持久性、降低毒性并解决抗原逃脱问题。

同时，竞争格局日益聚焦于如何在专有平台优势与加速临床开发的合作模式之间取得平衡。许可和共同开发契约使新参与企业能够利用成熟的载体技术和生产经验，而现有企业则透过强有力的证据生成和上市后监测来寻求临床差异化。商业活动强调整合价值提案，将临床培训、报销支援和结果追踪相结合，以降低在医疗保健系统中实施的风险。因此，竞争优势越来越取决于能否将科学差异化、可扩展的生产能力和切实的商业化支持结合在一起。

产业领导者行动计画：将製造韧性、证据生成、支付方合作和扩大设施准备度联繫起来，以加速永续获取

行业领导者应优先采取一系列合作行动，将科学创新与营运扩充性和市场进入准备工作相结合。首先，投资建立灵活的生产架构，以支援自体和异体治疗流程，从而能够快速应对需求波动和关税导致的采购变化。其次，建立健全的品质体系，并为关键试剂和一次性组件提供冗余供应，以最大限度地减少生产中断，确保患者治疗计划的顺利进行。第三，透过与治疗中心和註册机构合作，加速产生真实世界证据，记录长期治疗结果和安全性讯号，这些证据可作为医保报销谈判的基础。

同时，企业应与支付方建立伙伴关係，探索与持续疗效指标挂钩的按绩效付费合约和风险分担模式，这将有助于在临床第一线儘早推广应用。在临床方面，企业应扩大训练计画和认证途径，以便在更多医院和门诊肿瘤中心安全用药，从而缩短治疗启动时间，改善病患就医途径。最后，企业应在生产和监管方面采取策略性在地化措施，以平衡成本、上市速度和本地市场准入要求。这些措施将增强企业韧性，使产品价值与医疗系统需求相契合，并加速将科研成果转化为病患获益。

采用透明的混合方法，结合相关人员访谈、文献综述、监管审查和营运案例研究，得出切实可行的建议。

本研究整合了一级资讯来源和二级资讯来源，以现代科学和商业性实践为基础，得出有证据支持的结论。一级资讯来源包括对临床研究人员、生产专业人员、支付方和各治疗中心的营运负责人进行的结构化访谈，以收集关于产能限制、供应链风险和实施障碍的实地观点。二手资料分析涵盖了同行评审文献、监管指导文件、会议报告和公司披露信息，以综合考虑临床疗效、安全性趋势和技术进步。

此分析方法结合了主题综合和比较营运评估，以识别产能瓶颈和策略应对措施。製造规模扩大和分散式生产模式的案例研究为切实可行的建议奠定了基础。调查方法始终强调资料限制的透明度，例如不同适应症的临床证据成熟度差异以及不断变化的监管环境。对区域监管差异和供应链变异性的考量指导了情境规划和风险缓解提案。伦理考量和以病人为中心的结果是解释框架的核心，研究团队采取了严格的检验程序，以确保其对决策者的可信度和相关性。

策略要务综合分析，重点阐述了製造业韧性、证据生成和支付方合作对于实现科学潜力的重要性。

总之，CAR-T细胞疗法正处于一个关键的转折点，只有科学创新、生产能力和商业策略能够协同运作，才能为更广泛的患者群体带来福祉。儘管建筑工程和下一代设计领域的技术进步不断拓展着治疗的可能性，但供应链以及营运对政策变化的反应速度将决定这些治疗方法何时能够成为常规治疗方案。监管的灵活性以及支付方围绕基于结果的模式的积极参与，是将临床获益转化为永续可及性的关键槓桿。

从设想到实践，需要对生产韧性、证据产生和临床准备进行协同投资，并积极与包括监管机构、支付方和医疗服务提供相关人员的利益相关者合作。能够将技术差异化与务实的营运设计和区域策略相结合的机构，将获得最大的临床和商业性效益。最终，CAR-T疗法的未来取决于分子创新以及将疗法传递给患者的系统的韧性。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

• 扩大患者获得异基因现成CAR-T疗法的机会
• 双靶向和强化型CAR-T细胞构建体的出现，提高了安全性
• 整合自动化製造平台以缩短CAR-T生产时间
• 引入新型基因编辑工具以最大程度地减少CAR T细胞的脱靶效应
• 开发结合CAR-T细胞疗法和免疫查核点抑制剂的联合治疗
• 在产生真实世界证据以指导CAR-T细胞疗法的定价和报销策略方面取得进展
• 监管协调工作旨在加速CAR-T细胞疗法的全球核准进程。
• 在临床中心采用照护现场生产模式，以提高治疗的可近性。
• 将CAR-T细胞疗法的适应症扩大至全球固体癌治疗领域。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依适应症分類的 CAR-T 细胞疗法市场

• 白血病
  • 急性淋巴性白血病
  • 急性骨髓性白血病
• 多发性骨髓瘤
• 非何杰金氏淋巴瘤
  • 瀰漫性大B细胞淋巴瘤
  • 滤泡性淋巴瘤
  • 套细胞淋巴瘤

第九章 CAR-T细胞疗法市场（依细胞来源划分）

• 同种异体移植
• 自有住房

第十章 CAR-T细胞疗法市场（按世代划分）

• 第一代
• 第四代
• 第二代
• 第三代

第十一章 CAR-T细胞疗法市场按治疗线划分

• 一线治疗
• 復发/难治性

第十二章 CAR-T细胞疗法市场（以标靶抗原划分）

• BCMA
• CD19

第十三章：依最终用户分類的CAR-T细胞疗法市场

• 学术研究机构
• 医院
• 门诊肿瘤中心
• 专科诊所

14. 各地区的 CAR-T 细胞疗法市场

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十五章：按组别分類的CAR-T细胞疗法市场

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第十六章：各国CAR-T细胞疗法市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十七章 竞争格局

• 2024年市占率分析
• FPNV定位矩阵，2024
• 竞争分析
  • Novartis AG
  • Gilead Sciences, Inc.
  • Bristol-Myers Squibb Company
  • Johnson & Johnson
  • Legend Biotech Corporation
  • Miltenyi Biotec GmbH
  • Allogene Therapeutics, Inc.
  • Cellectis SA
  • Autolus Therapeutics plc
  • Poseida Therapeutics, Inc.

The CAR T-cell Therapy Market is projected to grow by USD 13.87 billion at a CAGR of 15.06% by 2032.

KEY MARKET STATISTICS
Base Year [2024]	USD 4.51 billion
Estimated Year [2025]	USD 5.19 billion
Forecast Year [2032]	USD 13.87 billion
CAGR (%)	15.06%

A concise strategic orientation to CAR T-cell therapy integrating scientific progress, manufacturing realities, regulatory dynamics, and commercial access considerations

The landscape of CAR T-cell therapy sits at the intersection of cutting-edge immuno-oncology science and complex commercial execution. This executive summary synthesizes clinical progress, translational innovations, regulatory momentum, manufacturing maturation, and shifting care delivery models that collectively define the current state of CAR T field. It is intended to orient executives, clinical leaders, investors, and policy makers to the forces shaping development priorities and operational decisions.

Beginning with a succinct review of therapeutic mechanisms and indication-specific clinical performance, the summary transitions to pragmatic considerations such as manufacturing capacity, supply chain resilience, and evolving site-of-care dynamics. Throughout, emphasis rests on actionable insights that link scientific advances to commercial feasibility. The narrative highlights how modular manufacturing platforms, antigen selection strategies, and next-generation constructs are translating into differentiated clinical profiles and new usage paradigms. In parallel, payor engagement and real-world evidence generation are emerging as critical determinants of access and uptake.

Taken together, the introduction frames subsequent sections by clarifying how discrete technological, regulatory, and economic developments are converging to reshape CAR T strategy across stakeholders, supporting informed decisions about investment, partnership, and operational design.

How technical, regulatory, manufacturing, and commercial shifts are jointly reconfiguring CAR T development pathways and patterns of patient access

CAR T-cell therapy is undergoing a series of transformative shifts that extend beyond incremental product improvements to alter the structure of development and delivery. Advances in vector engineering, costimulatory domain selection, and antigen targeting are expanding therapeutic applicability while simultaneously influencing safety and durability profiles. These technical evolutions are complemented by manufacturing innovations such as decentralized and automated platforms that shorten production timelines and lower per-dose operational complexity. As these technical shifts progress, they create opportunities for novel commercial models that blend centralized expertise with point-of-care delivery.

Regulatory pathways are adapting in parallel, with agencies showing increasing willingness to consider real-world evidence and adaptive development strategies that balance expedited access with long-term safety monitoring. Meanwhile, health systems are recalibrating infrastructure to support CAR T administration outside of traditional inpatient settings, and payors are experimenting with outcome-based contracting to align cost and clinical benefit. Taken together, these shifts are driving a transition from single-product, high-cost interventions toward more scalable, evidence-driven programs that prioritize durable outcomes and broader patient access. Stakeholders that anticipate and align with these shifts will be better positioned to convert scientific leadership into sustained clinical and commercial impact.

Operational and strategic responses to 2025 tariff shifts that reshape supply chain resilience, manufacturing footprint decisions, and clinical trial logistics

The introduction of new United States tariff measures in 2025 has introduced a tangible variable into the economics and logistics of advanced cell therapies. Tariffs applied to imported raw materials, single-use components, and specific bioprocessing equipment increase upstream costs and create uncertainty in supplier selection. This dynamic incentivizes manufacturers and clinical centers to re-evaluate sourcing strategies, explore alternative suppliers, and consider increased vertical integration of critical supply chains. In the near term, procurement cycles lengthen as contracting teams assess tariff impacts and negotiate revised terms.

Beyond procurement, tariff-driven cost pressures influence decisions around manufacturing footprint. Organizations may accelerate investments in domestic manufacturing capacity to reduce exposure to cross-border duties, or they may pursue regional partnerships that localize key steps such as vector production and fill-finish operations. Clinical trial sponsors will need to revisit budgeting assumptions and may prioritize sites with proximate manufacturing or supply redundancy to mitigate logistical risk. In parallel, hospitals and outpatient centers that provide infusion services must adapt planning for consumable inventory and capital equipment procurement.

Taken together, tariffs in 2025 do not change the scientific promise of CAR T therapies, but they do alter operational calculus. Stakeholders who adopt proactive supply chain diversification, strategic onshoring where feasible, and collaborative contracting with suppliers will reduce disruption and preserve treatment continuity for patients while maintaining momentum in development and commercialization.

Segmentation-driven insights that reveal how indication, cell source, generation, therapeutic line, antigen targeting, and care settings define development and commercialization pathways

Detailed segmentation uncovers nuanced drivers and distinct opportunity spaces across therapeutic and delivery domains. By indication the market spans Leukemia, which itself is subdivided into Acute Lymphoblastic Leukemia and Acute Myeloid Leukemia, Multiple Myeloma, and Non Hodgkin Lymphoma with Diffuse Large B Cell Lymphoma, Follicular Lymphoma, and Mantle Cell Lymphoma representing specific clinical subtypes; each indication carries unique response expectations, safety considerations, and evidentiary needs that influence trial design and commercialization strategy. Considering cell source, therapies derived from Allogeneic sources offer the promise of off-the-shelf dosing and faster time-to-treatment, while Autologous approaches remain prominent where individualized manufacturing aligns with established safety and efficacy precedents.

Generational differentiation also shapes clinical and operational profiles; First Generation constructs established proof of concept, Second Generation products introduced optimized costimulatory domains, Third Generation approaches combine multiple signaling elements for enhanced persistence, and Fourth Generation designs incorporate engineered functionalities such as cytokine expression or safety switches to broaden therapeutic potential. Line of therapy segmentation, including Frontline versus Relapsed Refractory use, dictates trial endpoints and payer conversations since earlier-line adoption prioritizes safety and long-term benefit whereas relapsed refractory contexts emphasize rapid response. Target antigen selection, notably BCMA and CD19, continues to drive indication-specific strategies and companion diagnostics development. Finally, end user segmentation across Academic Research Institutes, Hospitals, Outpatient Oncology Centers, and Specialty Clinics determines where investments in training, infrastructure, and care pathways will be most impactful, influencing rollout sequencing and provider partnerships.

How regional regulatory environments, manufacturing strategies, and care delivery capacity are directing differentiated CAR T access across global markets

Regional dynamics exert a powerful influence on regulatory expectations, manufacturing strategy, and care delivery models. In the Americas, dense networks of specialized treatment centers, a historically active venture ecosystem, and flexible regulatory pathways have catalyzed early clinical adoption and commercialization strategies that emphasize domestic manufacturing and real-world evidence generation. In contrast, Europe, Middle East & Africa presents a mosaic of regulatory regimes and heterogeneous reimbursement systems that require tailored health economic arguments and localized engagement plans, while also offering opportunities for regional manufacturing hubs that can serve multiple markets.

Asia-Pacific exhibits rapid capacity building, increasing domestic investment into cell therapy platforms, and an expanding pool of clinical trial sites that can accelerate patient accrual and comparative effectiveness research. Differences in infrastructure, workforce training, and reimbursement policy across these regions shape the pace and scale of access; as a result, manufacturers are adopting region-specific manufacturing footprints, regulatory strategies, and commercial partnerships to optimize launch sequencing and pricing models. Cross-regional collaboration, including licensing, co-development, and strategic manufacturing alliances, emerges as a practical pathway to reconcile global ambition with local realities and regulatory nuance.

Corporate strategies and collaborative models that drive competitive advantage through manufacturing scale, construct innovation, and integrated commercial support

Leading organizations in the CAR T ecosystem are advancing diversified portfolios across construct design, antigen targeting, and manufacturing modalities while pursuing strategic alliances to secure supply chains and broaden clinical reach. Industry participants are investing in modular, automated manufacturing platforms to reduce cycle times and improve reproducibility, and they are forging partnerships with academic centers and contract manufacturing organizations to expand capacity. Several companies are differentiating through next-generation engineering approaches that focus on enhancing persistence, reducing toxicities, and enabling multi-antigen targeting to address antigen escape.

At the same time, competitive dynamics reflect a balance between proprietary platform advantages and collaborative models that accelerate clinical development. Licensing agreements and co-development arrangements enable newer entrants to leverage established vector and manufacturing know-how, while incumbents seek to protect clinical differentiation through robust evidence generation and post-market surveillance. Commercial activities emphasize integrated value propositions that combine clinical training, reimbursement support, and outcomes tracking to de-risk adoption for health systems. As a result, competitive advantage increasingly derives from the ability to align scientific differentiation with scalable manufacturing and pragmatic commercialization support.

Action plans for industry leaders to link manufacturing resilience, evidence generation, payer engagement, and expanded site readiness to accelerate sustainable access

Industry leaders should prioritize a set of coordinated actions that connect scientific innovation with operational scalability and market access readiness. First, invest in flexible manufacturing architectures that support both autologous and allogeneic workflows, enabling rapid response to demand shifts and tariff-induced sourcing variability. Second, embed robust quality systems and supply redundancy for critical reagents and single-use components to minimize production interruptions and preserve patient schedules. Third, accelerate generation of real-world evidence by partnering with treatment centers and registries to document long-term outcomes and safety signals that underpin reimbursement discussions.

In parallel, companies should cultivate payer partnerships that explore outcome-based contracting and risk-sharing models aligned to durable response metrics, facilitating earlier adoption in frontline settings. From a clinical perspective, expand training programs and accreditation pathways to enable safe administration across a broader range of hospitals and outpatient oncology centers, thereby reducing time-to-treatment and improving patient access. Finally, adopt strategic regionalization for manufacturing and regulatory engagement that balances cost, speed-to-market, and local market access imperatives. These combined steps will strengthen resilience and align product value with health system needs, accelerating the conversion of scientific promise into patient benefit.

A transparent mixed-methods approach combining stakeholder interviews, literature synthesis, regulatory review, and operational case studies to inform practical recommendations

This research synthesized primary and secondary sources to produce evidence-based insights grounded in contemporary scientific and commercial practice. Primary inputs included structured interviews with clinical investigators, manufacturing experts, payers, and operational leaders across treatment centers to capture on-the-ground perspectives about capacity constraints, supply chain risks, and adoption barriers. Secondary analysis encompassed peer-reviewed literature, regulatory guidance documents, conference proceedings, and company disclosures to triangulate clinical efficacy, safety trends, and technological advancements.

Analytical methods combined thematic synthesis with comparative operational assessment to identify capacity bottlenecks and strategic responses. Case studies of manufacturing scale-up and decentralized production models informed practical recommendations. Throughout the methodology, emphasis was placed on transparency around data limitations, including the variable maturity of clinical evidence across indications and the evolving regulatory landscape. Sensitivity to regional regulatory differences and supply chain volatility guided scenario planning and risk mitigation suggestions. Ethical considerations and patient-centric outcomes remain central to the interpretive framework, and the research team employed rigorous validation steps to ensure credibility and relevance for decision-makers.

Synthesis of strategic imperatives showing that scientific promise requires manufacturing resilience, evidence generation, and payer engagement to achieve broader access

In conclusion, CAR T-cell therapy stands at a decisive inflection point where scientific innovation, manufacturing capability, and commercial strategy must align to deliver broader patient impact. Technical progress in construct engineering and next-generation designs continues to expand therapeutic potential, while operational responses to supply chain and policy changes will determine the pace at which those therapies become routine care options. Regulatory flexibility and payer willingness to engage around outcomes-based models are critical levers to translate clinical benefit into sustainable access.

Moving from promise to practice requires coordinated investments in manufacturing resilience, evidence generation, and clinical site readiness, together with proactive stakeholder engagement across regulators, payers, and providers. Organizations that synchronize technical differentiation with pragmatic operational design and regional strategy will capture the greatest clinical and commercial upside. Ultimately, the future of CAR T depends not only on molecular innovation but equally on the robustness of the systems that deliver these therapies to patients in need.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Expansion of allogeneic off-the-shelf CAR T therapies to broaden patient access
• 5.2. Emergence of dual-target and armored CAR T constructs for enhanced safety profiles
• 5.3. Integration of automated manufacturing platforms to reduce CAR T production times
• 5.4. Implementation of novel gene editing tools to minimize off-target effects in CAR T cells
• 5.5. Development of combination regimens pairing CAR T-cell therapy with immune checkpoint inhibitors
• 5.6. Advancements in real-world evidence generation to inform pricing and reimbursement strategies for CAR T
• 5.7. Regulatory harmonization efforts to accelerate global approval pathways for CAR T-cell treatments
• 5.8. Adoption of point-of-care manufacturing models within clinical centers to improve treatment accessibility
• 5.9. Expansion of CAR T-cell therapy indications into solid tumor oncology pipelines worldwide

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. CAR T-cell Therapy Market, by Indication

• 8.1. Leukemia
  • 8.1.1. Acute Lymphoblastic Leukemia
  • 8.1.2. Acute Myeloid Leukemia
• 8.2. Multiple Myeloma
• 8.3. Non Hodgkin Lymphoma
  • 8.3.1. Diffuse Large B Cell Lymphoma
  • 8.3.2. Follicular Lymphoma
  • 8.3.3. Mantle Cell Lymphoma

9. CAR T-cell Therapy Market, by Cell Source

• 9.1. Allogeneic
• 9.2. Autologous

10. CAR T-cell Therapy Market, by Generation

• 10.1. First Generation
• 10.2. Fourth Generation
• 10.3. Second Generation
• 10.4. Third Generation

11. CAR T-cell Therapy Market, by Line Of Therapy

• 11.1. Frontline
• 11.2. Relapsed Refractory

12. CAR T-cell Therapy Market, by Target Antigen

• 12.1. BCMA
• 12.2. CD19

13. CAR T-cell Therapy Market, by End User

• 13.1. Academic Research Institutes
• 13.2. Hospitals
• 13.3. Outpatient Oncology Centers
• 13.4. Specialty Clinics

14. CAR T-cell Therapy Market, by Region

• 14.1. Americas
  • 14.1.1. North America
  • 14.1.2. Latin America
• 14.2. Europe, Middle East & Africa
  • 14.2.1. Europe
  • 14.2.2. Middle East
  • 14.2.3. Africa
• 14.3. Asia-Pacific

15. CAR T-cell Therapy Market, by Group

• 15.1. ASEAN
• 15.2. GCC
• 15.3. European Union
• 15.4. BRICS
• 15.5. G7
• 15.6. NATO

16. CAR T-cell Therapy Market, by Country

• 16.1. United States
• 16.2. Canada
• 16.3. Mexico
• 16.4. Brazil
• 16.5. United Kingdom
• 16.6. Germany
• 16.7. France
• 16.8. Russia
• 16.9. Italy
• 16.10. Spain
• 16.11. China
• 16.12. India
• 16.13. Japan
• 16.14. Australia
• 16.15. South Korea

17. Competitive Landscape

• 17.1. Market Share Analysis, 2024
• 17.2. FPNV Positioning Matrix, 2024
• 17.3. Competitive Analysis
  • 17.3.1. Novartis AG
  • 17.3.2. Gilead Sciences, Inc.
  • 17.3.3. Bristol-Myers Squibb Company
  • 17.3.4. Johnson & Johnson
  • 17.3.5. Legend Biotech Corporation
  • 17.3.6. Miltenyi Biotec GmbH
  • 17.3.7. Allogene Therapeutics, Inc.
  • 17.3.8. Cellectis S.A.
  • 17.3.9. Autolus Therapeutics plc
  • 17.3.10. Poseida Therapeutics, Inc.

LIST OF FIGURES

• FIGURE 1. GLOBAL CAR T-CELL THERAPY MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2032 (%)
• FIGURE 13. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. GCC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. EUROPEAN UNION CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. BRICS CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. G7 CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. NATO CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 30. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 31. CAR T-CELL THERAPY MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 32. CAR T-CELL THERAPY MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. CAR T-CELL THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL CAR T-CELL THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL CAR T-CELL THERAPY MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE LYMPHOBLASTIC LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACUTE MYELOID LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY DIFFUSE LARGE B CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY DIFFUSE LARGE B CELL LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY DIFFUSE LARGE B CELL LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY DIFFUSE LARGE B CELL LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY DIFFUSE LARGE B CELL LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY DIFFUSE LARGE B CELL LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY REGION, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ALLOGENEIC, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY AUTOLOGOUS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FIRST GENERATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOURTH GENERATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOURTH GENERATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOURTH GENERATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOURTH GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FOURTH GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SECOND GENERATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY THIRD GENERATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FRONTLINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FRONTLINE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FRONTLINE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FRONTLINE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FRONTLINE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY FRONTLINE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY RELAPSED REFRACTORY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY RELAPSED REFRACTORY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY RELAPSED REFRACTORY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY RELAPSED REFRACTORY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY RELAPSED REFRACTORY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY RELAPSED REFRACTORY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY BCMA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY BCMA, BY REGION, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY BCMA, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY BCMA, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY BCMA, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY BCMA, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 121. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CD19, BY REGION, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CD19, BY REGION, 2025-2032 (USD MILLION)
• TABLE 123. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CD19, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CD19, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 125. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CD19, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY CD19, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 127. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 129. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 131. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 133. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY ACADEMIC RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 135. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 137. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 139. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 141. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY OUTPATIENT ONCOLOGY CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY OUTPATIENT ONCOLOGY CENTERS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 143. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY OUTPATIENT ONCOLOGY CENTERS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY OUTPATIENT ONCOLOGY CENTERS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 145. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY OUTPATIENT ONCOLOGY CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY OUTPATIENT ONCOLOGY CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 147. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 149. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 151. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 153. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 155. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 156. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 157. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 158. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 159. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
• TABLE 160. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
• TABLE 161. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
• TABLE 162. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2025-2032 (USD MILLION)
• TABLE 163. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
• TABLE 164. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
• TABLE 165. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
• TABLE 166. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
• TABLE 167. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 168. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 169. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
• TABLE 170. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2025-2032 (USD MILLION)
• TABLE 171. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 172. AMERICAS CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 173. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 174. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 175. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 176. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 177. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
• TABLE 178. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
• TABLE 179. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
• TABLE 180. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2025-2032 (USD MILLION)
• TABLE 181. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
• TABLE 182. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
• TABLE 183. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
• TABLE 184. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
• TABLE 185. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 186. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 187. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
• TABLE 188. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2025-2032 (USD MILLION)
• TABLE 189. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 190. NORTH AMERICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 191. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 192. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 193. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 194. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 195. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
• TABLE 196. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
• TABLE 197. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
• TABLE 198. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2025-2032 (USD MILLION)
• TABLE 199. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
• TABLE 200. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
• TABLE 201. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
• TABLE 202. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
• TABLE 203. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 204. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 205. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
• TABLE 206. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2025-2032 (USD MILLION)
• TABLE 207. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 208. LATIN AMERICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 209. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 210. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 211. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 212. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 213. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
• TABLE 214. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
• TABLE 215. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
• TABLE 216. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2025-2032 (USD MILLION)
• TABLE 217. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
• TABLE 218. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
• TABLE 219. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
• TABLE 220. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
• TABLE 221. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 222. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 223. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
• TABLE 224. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2025-2032 (USD MILLION)
• TABLE 225. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 226. EUROPE, MIDDLE EAST & AFRICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 227. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 228. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 229. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 230. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 231. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
• TABLE 232. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
• TABLE 233. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
• TABLE 234. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2025-2032 (USD MILLION)
• TABLE 235. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
• TABLE 236. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
• TABLE 237. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
• TABLE 238. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
• TABLE 239. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 240. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 241. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
• TABLE 242. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2025-2032 (USD MILLION)
• TABLE 243. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 244. EUROPE CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 245. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 246. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 247. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 248. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 249. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
• TABLE 250. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
• TABLE 251. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
• TABLE 252. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2025-2032 (USD MILLION)
• TABLE 253. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
• TABLE 254. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
• TABLE 255. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
• TABLE 256. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
• TABLE 257. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 258. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 259. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
• TABLE 260. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2025-2032 (USD MILLION)
• TABLE 261. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 262. MIDDLE EAST CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 263. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 264. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 265. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 266. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 267. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
• TABLE 268. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
• TABLE 269. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
• TABLE 270. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2025-2032 (USD MILLION)
• TABLE 271. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
• TABLE 272. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
• TABLE 273. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
• TABLE 274. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
• TABLE 275. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 276. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 277. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
• TABLE 278. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2025-2032 (USD MILLION)
• TABLE 279. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 280. AFRICA CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 281. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 282. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 283. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 284. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 285. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
• TABLE 286. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
• TABLE 287. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
• TABLE 288. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2025-2032 (USD MILLION)
• TABLE 289. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
• TABLE 290. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
• TABLE 291. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
• TABLE 292. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
• TABLE 293. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 294. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 295. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
• TABLE 296. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2025-2032 (USD MILLION)
• TABLE 297. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 298. ASIA-PACIFIC CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 299. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 300. GLOBAL CAR T-CELL THERAPY MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 301. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 302. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 303. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 304. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 305. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
• TABLE 306. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
• TABLE 307. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
• TABLE 308. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2025-2032 (USD MILLION)
• TABLE 309. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
• TABLE 310. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
• TABLE 311. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
• TABLE 312. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
• TABLE 313. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 314. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MILLION)
• TABLE 315. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2018-2024 (USD MILLION)
• TABLE 316. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY TARGET ANTIGEN, 2025-2032 (USD MILLION)
• TABLE 317. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 318. ASEAN CAR T-CELL THERAPY MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
• TABLE 319. GCC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 320. GCC CAR T-CELL THERAPY MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 321. GCC CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
• TABLE 322. GCC CAR T-CELL THERAPY MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
• TABLE 323. GCC CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2018-2024 (USD MILLION)
• TABLE 324. GCC CAR T-CELL THERAPY MARKET SIZE, BY LEUKEMIA, 2025-2032 (USD MILLION)
• TABLE 325. GCC CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2018-2024 (USD MILLION)
• TABLE 326. GCC CAR T-CELL THERAPY MARKET SIZE, BY NON HODGKIN LYMPHOMA, 2025-2032 (USD MILLION)
• TABLE 327. GCC CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2018-2024 (USD MILLION)
• TABLE 328. GCC CAR T-CELL THERAPY MARKET SIZE, BY CELL SOURCE, 2025-2032 (USD MILLION)
• TABLE 329. GCC CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2018-2024 (USD MILLION)
• TABLE 330. GCC CAR T-CELL THERAPY MARKET SIZE, BY GENERATION, 2025-2032 (USD MILLION)
• TABLE 331. GCC CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
• TABLE 332. GCC CAR T-CELL THERAPY MARKET SIZE, BY LINE OF THERAPY, 2025-2032 (USD MI